UTMD
Utah Medical Products, Inc.58.43
+0.94+1.64%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
187.31MP/E (TTM)
16.51Basic EPS (TTM)
3.54Dividend Yield
0.02%Recent Filings
10-K
8-K
2025 revenues fell 6%
Utah Medical Products reported 2025 revenues down 6% to $38.5M from $40.9M, missing projections due to PendoTECH OEM plunge, China distributor cancellation, and softer OUS Filshie sales—yet margins held firm at 57.1% gross and 29.6% operating. Cash climbed to $85.8M despite $8.4M share buybacks and $4.0M dividends. Buybacks cushioned EPS drop to $3.483.
10-Q
Q3 FY2025 results
UTMD's Q3 sales fell 1.9% y/y to $9.8M, yet neonatal devices surged 27% while gynecology dipped 3%; gross margin slipped to 57.1% from 58.0% on lower absorption. Operating income dropped 21.9% y/y to $2.6M (26.6% margin), hit by a $395 bad debt reserve for China distributor cancellations and higher G&A. Diluted EPS of $0.82 on 3,207k shares beat net income decline thanks to buybacks. Cash swelled to $84M, FCF hit $10.95M (derived); no debt. Share repurchases continue. Filshie litigation lingers.
8-K
Appoints director, boosts dividend
Utah Medical Products expanded its board from five to six members on October 31, 2025, appointing Kevin Timken, ex-legal counsel with 25 years advising UTMD on SEC matters, to the Audit and Compensation Committees. He got 10,000 stock options at $58.10/share vesting over four years, plus standard quarterly fees. On November 4, the board hiked its quarterly dividend 1.6% to $0.31/share, payable January 5, 2026. Board adds SEC savvy.
8-K
Q3 revenues dip 2% on cancellations
Utah Medical Products reported Q3 2025 revenues down 2% to $9.8M and 9M sales off 7% to $29.5M, hit hard by a China distributor's cancellation of non-cancellable orders, costing $581K in revenue and a $395K bad debt reserve. Operating income plunged 22% in Q3 amid lower absorption and higher expenses, yet share repurchases cushioned EPS decline to 20%. Tariffs jacked up costs; full-year sales now eyed 7% below 2024.
IPO
Website
Employees
Sector
Industry
BFLY
Butterfly Network, Inc.
3.34+0.12
CNMD
CONMED Corporation
39.20-1.12
ICUI
ICU Medical, Inc.
147.07-0.96
MASI
Masimo Corporation
134.52-2.88
MDT
Medtronic plc.
97.72-0.85
MHUA
Meihua International Medical Te
7.61-6.41
MMSI
Merit Medical Systems, Inc.
86.85+0.44
RMD
ResMed Inc.
247.34-5.73
UEEC
United Health Products, Inc.
0.06+0.00
UFPT
UFP Technologies, Inc.
217.74-0.08